A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. (FALCON)

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of the Combination of GLPG2451 and GLPG2222, With or Without GLPG2737, in Adult Subjects With Cystic Fibrosis

This is a Phase Ib, multi-center, open-label, nonrandomized multiple cohorts study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of a combination treatment of GLPG2451 and GLPG2222, with and without GLPG2737, in adult subjects with Cystic Fibrosis.

Study Overview

• Status: Completed
• Conditions: Cystic Fibrosis
• Intervention / Treatment: Drug: GLPG2451 dose regimen A; Drug: GLPG2222; Drug: GLPG2737; Drug: GLPG2451 dose regimen B

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Phase 1

Contacts and Locations

Study Locations

• Belgium
  • Antwerp, Belgium
    • Study Site BEL004
  • Brussels, Belgium
    • Study Site BEL003
  • Gent, Belgium
    • Study Site BEL002
  • Leuven, Belgium
    • Study Site BEL001
• Bulgaria
  • Sofia, Bulgaria
    • Study Site BGR001
• Germany
  • Berlin, Germany
    • Study Site DEU001
  • Essen, Germany
    • Study Site DEU002
• Greece
  • Thessaloníki, Greece
    • Study Site GRC001
• Netherlands
  • Amsterdam, Netherlands
    • Study Site NLD002
  • Utrecht, Netherlands
    • Study Site NLD001
• Serbia
  • Belgrade, Serbia
    • Study Site SRB001
• Sweden
  • Göteborg, Sweden
    • Study Site SWE001
  • Stockholm, Sweden
    • Study Site SWE002
• United Kingdom
  • Birmingham, United Kingdom
    • Study Site GBR003
  • Glasgow, United Kingdom
    • Study Site GBR004
  • Liverpool, United Kingdom
    • Study Site GBR005
  • London, United Kingdom, SW3 6NP
    • Study Site GBR007
  • Newcastle, United Kingdom
    • Study Site GBR006
  • Papworth Everard, United Kingdom
    • Study Site GBR001
  • Wythenshawe, United Kingdom
    • Study Site GBR002

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Female or male subject ≥18 years of age, on the day of signing the Informed Consent Form (ICF)
• Confirmed clinical diagnosis of cystic fibrosis (CF) (documented in the subject's medical record).

• Eligible cystic fibrosis transmembrane conductance regulator (CFTR) genotype at screening:

  • Cohort A: Homozygous for the F508del CFTR mutation
  • Cohort B: Heterozygous for the F508del CFTR mutation with a potentiator non-responsive mutation on the second allele
  • Cohort C: Homozygous for the F508del CFTR mutation
• A body weight of ≥40 kg at screening.
• Stable concomitant medication for pulmonary health for CF for at least 4 weeks prior to the first study drug administration and planned continuation of the same concomitant medication for the duration of the dosing period of the study. Subjects with diabetes mellitus and/or pancreatic insufficiency are eligible for the study provided they are on stable treatment (e.g. medication, diet, pancreatic enzyme replacement therapy) for at least 4 weeks prior to the first study drug administration in the opinion of the investigator.
• Forced expiratory volume in 1 second (FEV1): 40% ≤ FEV1 ≤ 90% of predicted normal for age, sex, and height at screening (pre- or post bronchodilator) at screening.
• Sweat chloride concentration ≥60 mmol/L at screening.
• Non-smoker and non-user of any nicotine and or cannabis containing products. A non-smoker is defined as an individual who has abstained from smoking for at least 1 year prior to the screening. A non-user is defined as an individual who has abstained from any nicotine containing products for at least 1 year prior to the screening.

Exclusion Criteria:

• History of or ongoing allergic bronchopulmonary aspergillosis.
• Medical history of cataract (or lens opacity) and/or glaucoma.
• Cataract (or lens opacity) and/or glaucoma determined by an ophthalmologist during the screening period.
• Unstable pulmonary status or respiratory tract infection (including rhinosinusitis) requiring a change in therapy within 4 weeks prior to the first study drug administration.
• History of clinically meaningful unstable or uncontrolled chronic disease that makes the subject unsuitable for inclusion in the study in the opinion of the investigator.
• Need for supplemental oxygen during the day, and >2 L/minute while sleeping.
• History of hepatic cirrhosis with portal hypertension (e.g., signs/symptoms of splenomegaly, esophageal varices).
• History of malignancy within the past 5 years (except for basal cell carcinoma of the skin with no evidence of recurrence and/or carcinoma in situ of the cervix that has been treated with no evidence of recurrence).
• Use of any moderate and strong inhibitor(s) or inducer(s) of CYP3A4 within 4 weeks prior to the first study drug administration (e.g., clarithromycin, itraconazole, ketoconazole, telithromycin, rifampin, carbamazepine).
• Use of CFTR modulator therapy (e.g., lumacaftor and/or ivacaftor) within 4 weeks prior to the first study drug administration.
• Use of any oral corticosteroid within 3 months of screening; or history of oral corticosteroid use for ≥30 days (cumulative) within 2 years of screening.
• Abnormal liver function test at screening; defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) and/or alkaline phosphatase and/or gamma-glutamyl transferase (GGT) ≥3× the upper limit of normal (ULN); and/or total bilirubin ≥1.5× the ULN.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NON_RANDOMIZED
• Interventional Model: SEQUENTIAL
• Masking: NONE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Cohort A - F508del homozygous; Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods.( Study Part I)	Drug: GLPG2451 dose regimen A; GLPG2451 oral suspension, daily.; Drug: GLPG2222; GLPG2222 tablet for oral use, daily.; Drug: GLPG2737; GLPG2737 capsules for oral use, daily.
EXPERIMENTAL: Cohort B - F508del heterozygous/potentiator nonresponsive; Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods. (study Part II)	Drug: GLPG2222; GLPG2222 tablet for oral use, daily.; Drug: GLPG2737; GLPG2737 capsules for oral use, daily.; Drug: GLPG2451 dose regimen B; GLPG2451 oral suspension, daily.
EXPERIMENTAL: Cohort C - F508del homozygous; Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods. (Study Part II)	Drug: GLPG2222; GLPG2222 tablet for oral use, daily.; Drug: GLPG2737; GLPG2737 capsules for oral use, daily.; Drug: GLPG2451 dose regimen B; GLPG2451 oral suspension, daily.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of subjects with adverse events.	To assess safety and tolerability of doses of GLPG2451 and GLPG2222 with or without GLPG2737 (Study Part I and Part II).	Up to 24 weeks after the last dose
Maximum observed plasma concentration (Cmax).	To characterize the pharmacokinetics (PK) of GLPG2451 and GLPG2222 with or without GLPG2737 (Study Part I).	Day 14
Maximum observed plasma concentration (Cmax).	To characterize the PK of GLPG2451 and GLPG2222 with or without GLPG2737 (Study Part I).	Day 28
Area under the plasma concentration-time curve from time zero until 24 hours (AUC0-24h).	To characterize the PK of GLPG2451 and GLPG2222 with or without GLPG2737 (Study Part I).	Day 14
Area under the plasma concentration-time curve from time zero until 24 hours (AUC0-24h).	To characterize the PK of GLPG2451 and GLPG2222 with or without GLPG2737 (Study Part I).	Day 28
Trough plasma concentration observed at the end of the dosing interval (24 hours post-dose) (Ctrough).	To characterize the PK of GLPG2451 and GLPG2222 with or without GLPG2737 (Study Part I and Part II).	Between Day 2 and Day 28
Change from baseline in sweat chloride concentration.	To assess changes in sweat chloride concentration after administration of the combination of GLPG2451 and GLPG2222 with or without GLPG2737 (Study Part II).	Between Day 1 pre-dose and Day 28
Change from baseline in percent predicted FEV1.	To assess changes in percent predicted FEV1 after administration of the combination of GLPG2451 and GLPG2222 with or without GLPG2737 (Study Part II).	Between Day 1 pre-dose and Day 28

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in sweat chloride concentration.	To assess changes in sweat chloride concentration after administration of the combination of GLPG2451 and GLPG2222 with or without GLPG2737 (Study Part I).	Between Day 1 pre-dose and Day 28
Change from baseline in percent predicted FEV1.	To assess changes in percent predicted FEV1 after administration of the combination of GLPG2451 and GLPG2222 with or without GLPG2737 (Study Part I).	Between Day 1 pre-dose and Day 28

Collaborators and Investigators

• Sponsor: Galapagos NV

Study record dates

Study Major Dates

• Study Start (ACTUAL): May 31, 2018
• Primary Completion (ACTUAL): March 11, 2019
• Study Completion (ACTUAL): March 11, 2019

Study Registration Dates

• First Submitted: April 27, 2018
• First Submitted That Met QC Criteria: May 16, 2018
• First Posted (ACTUAL): May 30, 2018

Study Record Updates

• Last Update Posted (ACTUAL): April 8, 2019
• Last Update Submitted That Met QC Criteria: April 4, 2019
• Last Verified: April 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Respiratory Tract Diseases; Lung Diseases; Infant, Newborn, Diseases; Genetic Diseases, Inborn; Pancreatic Diseases; Fibrosis; Cystic Fibrosis
• Other Study ID Numbers: GLPG2737-CL-105; 2017-001067-20 (EUDRACT_NUMBER)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No